"With the possible exception of fluoxetine (multiple brands), the vast majority of antidepressants are ineffective, and some may even be unsafe, for use in children and teens with major depressive disorder (MDD), new research shows.
Oleptro Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Oleptro (trazodone hydrochloride extended-release tablets) is a triazolopyridine antidepressant used to treat major depressive disorder (MDD) in adults. Common side effects of Oleptro include drowsiness, sedation, dizziness, lightheadedness, constipation, headache, blurred vision, nausea, vomiting, dry mouth, or change in sexual interest/ability.
The recommended starting dose of Oleptro is 150 mg once daily in adults. The dose may be increased by 75 mg/day every three days (i.e., start 225 mg on Day 4 of therapy). The maximum daily dose should not exceed 375 mg. Oleptro may interact with monoamine oxidase inhibitors (MAOIs), alcohol, barbiturates, other CNS depressants, ritonavir, ketoconazole, indinavir, itraconazole, carbamazepine, digoxin, phenytoin, serotonergic drugs, non-steroidal anti-inflammatory drugs (NSAIDs), aspirin, other drugs affecting coagulation or bleeding, or warfarin. Tell your doctor all medications you use. During pregnancy, Oleptro should be used only if prescribed. This medication may be passed in breast milk. Consult your doctor before breast-feeding.
Our Oleptro (trazodone hydrochloride extended-release tablets) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Patient Information in Detail?
Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.
Oleptro in Detail - Patient Information: Side Effects
Stop taking trazodone and call your doctor at once if you have a penis erection that is painful or lasts 6 hours or longer. This is a medical emergency and could lead to a serious condition that must be corrected with surgery.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any new or worsening symptoms such as: mood or behavior changes, anxiety, panic attacks, trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, aggressive, restless, hyperactive (mentally or physically), more depressed, or have thoughts about suicide or hurting yourself.
Stop taking trazodone and call your doctor at once if you have a serious side effect such as:
- extreme mood swings, restlessness, or sleep problems;
- dizziness, fainting, fast or pounding heartbeat;
- easy bruising or bleeding;
- agitation, hallucinations, fast heart rate, overactive reflexes, nausea, vomiting, diarrhea, loss of coordination;
- very stiff (rigid) muscles, high fever, confusion, fast or uneven heartbeats, tremors, feeling like you might pass out;
- headache, trouble concentrating, memory problems, weakness, loss of appetite, feeling unsteady, seizure, shallow breathing or breathing that stops; or
- chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling.
Less serious side effects may be more likely to occur, such as:
- mild headache;
- constipation; or
- blurred vision.
Read the entire detailed patient monograph for Oleptro (Trazodone Hydrochloride Extended-Release Tablets)
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Oleptro FDA Prescribing Information: Side Effects
The following serious adverse reactions are described elsewhere in the labeling:
- Clinical Worsening and Suicide Risk [see BOXED WARNING and WARNINGS AND PRECAUTIONS]
- Serotonin Syndrome or NMS-like Reactions [see WARNINGS AND PRECAUTIONS]
- QT Prolongation and Risk of Sudden Death [see WARNINGS AND PRECAUTIONS]
- Orthostatic Hypotension [see WARNINGS AND PRECAUTIONS]
- Abnormal bleeding events [see WARNINGS AND PRECAUTIONS]
- Priapism [see WARNINGS AND PRECAUTIONS]
- Hyponatremia [see WARNINGS AND PRECAUTIONS]
- Cognitive and Motor Impairment [see WARNINGS AND PRECAUTIONS]
- Discontinuation symptoms [see WARNINGS AND PRECAUTIONS]
The most common adverse reactions (reported in ≥ 5% and at twice the rate of placebo) are: somnolence/sedation, dizziness, constipation, vision blurred.
Table 2 presents the summary of adverse events (AEs) leading to discontinuation of Oleptro treatment with an incidence of at least 1% and at least twice that for placebo.
Table 2: AEs with
discontinuation as action taken ( ≥ 1% incidence and incidence 2x placebo)
N = 202
|Confusional state||2 (1.0%)|
|Coordination abnormal||2 (1.0%)|
|Balance disorder / Gait disturbance||2 (1.0%)|
Clinical Studies Experience
The data described below reflects exposure in a clinical trial of 406 patients, including 204 exposed to placebo and 202 exposed to Oleptro. Patients were between 18-80 years of age and 69.3% and 67.5% of patients had at least one previous episode of depression in the last 24 months in the placebo and active-treated group, respectively. In individual patients, doses were flexible and ranged from 150 to 375 mg per day. The mean daily dose during the 6-week treatment period was 310 mg. The tablets were administered orally and were given once a day for a total duration of 8 weeks, including the titration period.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Table 3 presents the summary of all treatment emergent AEs that occurred at an incidence of ≥ 5% in the Oleptro group, whether considered by the clinical investigator to be related to the study drug or not.
Table 3: Most Common
Treatment Emergent Adverse Events ( ≥ 5% of Patients on Active Treatment)
N = 204
N = 202
|Somnolence/Sedation||39 (19%)||93 (46%)|
|Headache||55 (27%)||67 (33%)|
|Dry mouth||26 (13%)||51 (25%)|
|Dizziness||25 (12%)||50 (25%)|
|Nausea||26 (13%)||42 (21%)|
|Fatigue||17 (8%)||30 (15%)|
|Diarrhea||23 (11%)||19 (9%)|
|Constipation||4 (2%)||16 (8%)|
|Back pain||7 (3%)||11 (5%)|
|Vision blurred||0 (0%)||11 (5%)|
Adverse events related to sexual dysfunction (regardless of causality) were reported by 4.9% and 1.5% of patients treated with Oleptro and placebo, respectively. In the Oleptro group, ejaculation disorders occurred in 1.5% of patients, decreased libido occurred in 1.5% of patients, and erectile dysfunction and abnormal orgasm < 1% of patients.
Vital Signs and Weight
There were no notable changes in vital signs (blood pressure, respiratory rate, pulse) or weight in either treatment group.
Following is a list of treatment-emergent adverse reactions with an incidence of ≥ 1% to < 5% (i.e., less common) in patients treated with Oleptro. This listing is not intended to include reactions (i) already listed in previous tables or elsewhere in the labeling (ii) for which the association with treatment is remote, (iii) which were so general as to be uninformative, and (iv) which were not considered to have significant clinical implications. Reactions are classified by body-system using the following definitions: frequent adverse reactions are those occurring in at least 1/100 patients; Infrequent adverse reactions are those occurring in less than 1/100 patients.
General Disorders and Administration Site Conditions- Frequent: edema; Infrequent: gait disturbance
Immune System Disorders- Infrequent: hypersensitivity
Psychiatric Disorders- Frequent: agitation, confusional state, disorientation
Respiratory, Thoracic and Mediastinal Disorders- Frequent: dyspnea
Vascular Disorders- Infrequent: flushing
Spontaneous reports regarding trazodone hydrochloride received from postmarketing experience include the following: abnormal dreams, agitation, alopecia, anxiety, aphasia, apnea, ataxia, breast enlargement or engorgement, cardiospasm, cerebrovascular accident, chills, cholestasis, clitorism, congestive heart failure, diplopia, edema, extrapyramidal symptoms, grand mal seizures, hallucinations, hemolytic anemia, hirsutism, hyperbilirubinemia, increased amylase, increased salivation, insomnia, leukocytosis, leukonychia, jaundice, lactation, liver enzyme alterations, methemoglobinemia, nausea/vomiting (most frequently), paresthesia, paranoid reaction, priapism [see WARNINGS AND PRECAUTIONS and PATIENT INFORMATION], pruritus, psoriasis, psychosis, rash, stupor, inappropriate ADH syndrome, tardive dyskinesia, unexplained death, urinary incontinence, urinary retention, urticaria, vasodilation, vertigo, and weakness.
Cardiovascular system effects which have been reported include the following: conduction block, orthostatic hypotension and syncope, palpitations, bradycardia, atrial fibrillation, myocardial infarction, cardiac arrest, arrhythmia, ventricular ectopic activity, including ventricular tachycardia and QT prolongation. In postmarketing surveillance, prolonged QT interval, Torsades de Pointes, and ventricular tachycardia have been reported with the immediate-release form of trazodone at doses of 100 mg per day or less [see WARNINGS AND PRECAUTIONS].
Read the entire FDA prescribing information for Oleptro (Trazodone Hydrochloride Extended-Release Tablets)
Additional Oleptro Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get tips on therapy and treatment.